primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma.
Eur J CancerJul 21, 2026 (epub)
Clinical ResearchOncology (Medical)
Alexander Cj van Akkooi, Michal Kicinski, Anne-Sophie Govaerts et al.
✦ AI-curated · Sources linked
In 30 seconds
The EORTC 2139 - Columbus-AD trial evaluated the efficacy and safety of adjuvant therapy with encorafenib and binimetinib versus placebo in patients with resected high-risk stage IIB/C BRAF V600E/K melanoma. This randomized controlled trial included 110 patients, revealing a 12-month recurrence-free survival (RFS) of 86% in the treatment group compared to 70% in the placebo group.
Key findings
- 12-month recurrence-free survival was 86% for encorafenib and binimetinib versus 70% for placebo.
- Distant metastasis-free survival at 12 months was 92% for the treatment group compared to 82% for placebo.
- 24% of patients experienced grade ≥3 treatment-related adverse events with the combination therapy.
Why it matters
This study highlights the potential benefit of adjuvant BRAF/MEK inhibitor therapy in reducing recurrence risk in high-risk melanoma patients, which may influence treatment strategies in this population.